MediciNova
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- $71.6M
- Introduction
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on the...
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 40
- Registration Number
- NCT05464784
- Locations
- 🇺🇸
Jubilee Clinical Research, Inc., Las Vegas, Nevada, United States
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 34
- Registration Number
- NCT04429555
- Locations
- 🇺🇸
Denver Health and Hospital Authority, Denver, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 230
- Registration Number
- NCT04057898
- Locations
- 🇺🇸
University of California, Orange, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 12
- Registration Number
- NCT04054206
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Garden Grove, California, United States
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 50
- Registration Number
- NCT03782415
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 28
- Registration Number
- NCT03533387
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 35
- Registration Number
- NCT02714036
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸South Shore Neurologic Associates, P.C., Patchogue, New York, United States
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 19
- Registration Number
- NCT02681055
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Scripps Research, La Jolla, California, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 15
- Registration Number
- NCT02503657
- Locations
- 🇺🇸
Penn State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 70
- Registration Number
- NCT02238626
- Locations
- 🇺🇸
Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States